Evidence map›Paper›PMID 42242227›Full record

ArticleCell reports. Medicine2026

HIV tri-specific killer engagers directly enhance NK cell function and safely expand NK cells in vivo.

Ross T Cromarty, Julien A Clain, Yvette Soigner, Tumpa Dasgupta, Kate Dixon, Kevin Nguyen, Hannah Flores, Emma Eungard, Joshua Walker, Josh Bjorgen and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ross T CromartyMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA. Electronic address: rcromart@umn.edu.
Julien A ClainDivision of Microbiology & Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
Yvette SoignerMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Tumpa DasguptaMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Kate DixonDepartment of Veterinary and Biomedical Sciences, University of Minnesota, St. Paul, MN, USA.
Kevin NguyenDivision of Microbiology & Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
Hannah FloresDivision of Microbiology & Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
Emma EungardMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Joshua WalkerMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Josh BjorgenMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Martin FelicesMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA; Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Justin HarperDivision of Microbiology & Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
Timothy W SchackerDivision of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Zachary DavisMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA; Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Mirko PaiardiniDivision of Microbiology & Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA; Department of Pathology & Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Jeffrey S MillerMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA; Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
ERASE HIV: Enterprise for Research and Advancements to Stop and Eradicate HIVUM1AI164562 · NIAID · EMORY UNIVERSITY · PI Deanna A Kulpa, Mirko Paiardini · 2021 to 2026
$30.0M
Reversing Immune Dysfunction for HIV-1 EradicationUM1AI164561 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI SUMIT K CHANDA, Paula M Cannon · 2021 to 2026
$30.0M
Viral Testing Core-Maintenance of the SPF Breeding Colonies at Yerkes National Primate Research CenterU42OD011023 · OD · EMORY UNIVERSITY · PI Joyce Kimberly Cohen · 2018 to 2026
$17.5M
Targeting off-the-shelf iPSC-derived natural killer cells against solid tumorsR35CA283892 · NCI · UNIVERSITY OF MINNESOTA · PI Jeffrey S. Miller · 2023 to 2026
$3.7M
NCI NIH HHS R35 CA283892NIAID NIH HHS UM1 AI164561NIAID NIH HHS UM1 AI164562NIH HHS P51 OD011132NIH HHS U42 OD011023
6 · The paper itself

Abstract

An HIV cure remains elusive, and many individuals develop comorbidities; therefore, new synergistic strategies to combat HIV are needed. Enhanced natural killer (NK) cell function associates with HIV elite control, primarily through antibody-dependent cellular cytotoxicity (ADCC). We generated tri-specific killer engagers (TriKEs) to enhance NK cell responses against HIV-infected cells. HIV TriKEs, one using the VRC01/07 antibody domains (VRC TriKE) and one using the CD4 ectodomain 1 (CD4 TriKE), promote NK cell function and killing of HIV target cells. NK cells expressing both CD38 and CD57 are major mediators of this function. We performed a dose-escalation study in SIV-uninfected rhesus macaques to assess the safety and pharmacodynamics of our CD4 TriKE. The TriKE is safe and effective at expanding peripheral and lymphoid NK cells in vivo. These findings support TriKEs as a promising safe immunotherapy to recognize and kill HIV-infected cells, with potential for combination cure strategies.

Indexed as

HIV-1HIV InfectionsKiller Cells, NaturalAnimalsAntibody-Dependent Cell CytotoxicityCD4 AntigensHumansMacaca mulattaSimian Immunodeficiency VirusCD4 AntigensADCCHIVimmunotherapyNK cellstri-specific killer engagers

Identifiers

PMID42242227
PMCPMC13400145

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.